Grant: Project Grant
Université de Montréal
$864,450.00
Identification of MYC-dependent vulnerabilities in breast cancer
FY 2021-22
Summary
Triple-negative breast cancer (TNBC) represents the tumor type with the poorest outcome. TNBCs frequently harbor alterations in the MYC oncogene, for which no direct treatment currently exists. To identify potential vulnerabilities in TNBC, we designed a cellular model expressing the MYC oncogene. We found that MYC promotes the expression of many receptors at the surface of cancer cells that could be targeted to treat TNBC. In this project, we will use breast cancer cells in culture, as well as pre-clinical models of TNBC, to assess the therapeutic targeting of these novel cell-surface receptors. Through this work, we hope to characterize these receptors in TNBC, while also providing answers about their druggability for potential TNBC treatment.
Department
Program
Project Grant
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
444188
Name
Roux Philippe
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Molecular & Cellular Biology of Cancer
Projecttitle
Identification of MYC-dependent vulnerabilities in breast cancer
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$864,450
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Breast Cancer; Myc; Pharmacological Inhibitors; Protein Phosphorylation; Proteomics; Rtk Signaling; Slitrk; Tnbc; Tumorigenesis
Abstract
Triple-negative breast cancer (TNBC) represents the tumor type with the poorest outcome. TNBCs frequently harbor alterations in the MYC oncogene, for which no direct treatment currently exists. To identify potential vulnerabilities in TNBC, we designed a cellular model expressing the MYC oncogene. We found that MYC promotes the expression of many receptors at the surface of cancer cells that could be targeted to treat TNBC. In this project, we will use breast cancer cells in culture, as well as pre-clinical models of TNBC, to assess the therapeutic targeting of these novel cell-surface receptors. Through this work, we hope to characterize these receptors in TNBC, while also providing answers about their druggability for potential TNBC treatment.
Competitiondate
202104
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Roux, Philippe
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $864,450~ $0~
